23 May 2018

ASX ANNOUNCEMENT

Assessment with L-Dex® Features at ALA

Brisbane, Australia - ImpediMed Limited (ASX: IPD) a global provider of medical technology to non-invasively measure, monitor and manage tissue composition and fluid status using bioimpedance spectroscopy (BIS), is pleased to announce that L-Dex® featured highly at the 12th Australasian Lymphology Association (ALA) conference held in Brisbane from 17th - 19th May 2018.

The ALA is the peak professional organisation in Australasia for lymphoedema management, research and education and their biennial conference is the premier lymphoedema event for the Asia Pacific. The conference was attended by internationally and nationally-renowned speakers and delegates. The program had an entire session dedicated to use of BIS for lymphoedema assessment.

There was a record attendance at this year’s conference. “We are delighted to report that the 12th ALA Conference, like the association has enjoyed very strong growth over the last four years. The ALA enjoys increasingly strong support from industry, including ImpediMed, one of the ALA’s Industry Partners," stated Leonie Naumann, President, Australasian Lymphology Association.

A post conference workshop sponsored by ImpediMed featured presentations by Louise Koelmeyer, Dr Sandi Hayes and Prof Leigh Ward. The workshop highlighted the SOZO® platform and was delivered to a "sold-out" audience. The purpose of the session was to educate clinicians on how SOZO can lead to more efficient clinical decision making to educate, support and empower a patient’s quality of life as a cancer survivor.

Richard Carreon
Managing Director & CEO

Media Contact:
Kyahn Williamson, WE Buchan
T: +61 3 9866 4722
E: kwilliamson@buchanwe.com.au

About ImpediMed
Founded and headquartered in Brisbane, Australia with US and European operations, ImpediMed is the world leader in the design and manufacture of medical devices employing bioimpedance spectroscopy (BIS) technologies for use in the non-invasive clinical assessment and monitoring of tissue composition and fluid status.
ImpediMed produces a family of FDA cleared and CE Marked medical devices, including SOZO® for multiple indications including heart failure and lymphoedema, sold in select markets globally.

For more information, visit www.impedimed.com.